Prof. Dr. Rainer Fietkau

Medizinische Fakultät Lehrstuhl für Strahlentherapie

The Effect of Lurbinectedin as a Monotherapy and in Combination with Ionizing Radiation on Sarcoma Cell Lines (2025) Alsheimer H, Schiller P, Semrau S, Grabenbauer F, Fietkau R, Distel L, Hildebrand L Journal article Quality of Life Identifies High-Risk Groups in Advanced Rectal Cancer Patients (2025) Zollner AL, Blasko D, Fitz T, Schweizer C, Fietkau R, Distel L Journal article Translationale Forschung in der Radioonkologie: Forschung mit dem Patienten für die Anwendung am Patienten (2025) Donaubauer AJ, Mogge L, Putz F, Haderlein M, Fietkau R, Corradini S, Gaipl U, Frey B Journal article Advancing offline magnetic resonance-guided prostate radiotherapy through dedicated imaging and deep learning-based automatic contouring of targets and neurovascular structures (2025) Schubert P, May M, Höfler D, Fautz HP, Hutter J, Merten R, Mansoorian S, et al. Journal article Chemoradiation-Altered Micromilieu of Glioblastoma Cells Particularly Impacts M1-like Macrophage Activation (2025) Shojaei M, Frey B, Putz F, Fietkau R, Gaipl U, Derer A Journal article Comparison of dose calculation approaches and clinical dose–response in image-guided head&neck brachytherapy of the oral cavity (2025) Schaller S, Strnad V, Schweizer C, Lubgan D, Merten R, Fietkau R, Bert C, Karius A Journal article No Survival Effect in Cell Lines with Different Growth Factor-Induced Division Rates, but with Different Fractionation Schemes (2025) Blanke L, Hildebrand L, Fietkau R, Distel L Journal article Prognostic Significance of Macrophage Phenotypes in Peri-Tumoral Normal Tissue of Early-Stage Breast Cancer (2025) Hirschmann M, Schnellhardt S, Rübner M, Segelhorst S, Ott O, Erber R, Daniel C, et al. Journal article Organ preservation after total neoadjuvant therapy for locally advanced rectal cancer (CAO/ARO/AIO-16): an open-label, multicentre, single-arm, phase 2 trial (2025) Gani C, Fokas E, Polat B, Ott O, Diefenhardt M, Königsrainer A, Böke S, et al. Journal article Corrigendum: Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC (Frontiers in Oncology, (2024), 14, (1460150), 10.3389/fonc.2024.1460150) (2025) Meidenbauer J, Wachter M, Schulz S, Mostafa N, Zülch L, Frey B, Fietkau R, et al. Journal article, Erratum